Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.

ABSTRACT:

Aims/hypothesis

Immunomodulators blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) have improved the treatment of a broad spectrum of cancers. These immune checkpoint inhibitors (ICIs) reactivate the immune system against tumour cells but can also trigger autoimmune side effects, including type 1 diabetes. Mesenchymal stem cell (MSC) therapy is the most prevalent cell therapy, with tissue-regenerating, anti-fibrosis and immunomodulatory functions provided by the secretome of the cells. Here, we examined whether systemic MSC treatment could prevent the development of type 1 diabetes in a NOD mouse model.

Methods

The purified PD-L1 monoclonal antibody was administered to induce diabetes

SUBMITTER: Kawada-Horitani E 

PROVIDER: S-EPMC9174328 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature